Neuro-feedback Therapy for Treating Tinnitus (TNTA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03773926|
Recruitment Status : Recruiting
First Posted : December 12, 2018
Last Update Posted : December 12, 2018
|Condition or disease||Intervention/treatment||Phase|
|Tinnitus Hearing Loss||Device: Neuro-feedback therapy||Not Applicable|
Many individuals with tinnitus have abnormal oscillatory brain activity in their temporal areas (Weisz et al. (2005), Schlee et al. (2014)). Led by this finding, attempts to normalize such localized pathological activity by neuro-feedback techniques have been tested (Dohrmann et al. (2007), Gütenspenger et al. (2017)). These attempts highlighted interindividual variability that can be explained by lack of selection of the patient population and lack of guidance through the therapy. The present study is aimed at addressing these issues by choosing more selectively a patient subpopulation (tinnitus associated with moderate hearing loss) and by implementing a guidance interface during the treatment.
The therapy will consist of 10 neuro-feedback training sessions of 29 minutes over 5 weeks. Each session will be composed of 6 blocks of 3 min in which the patient will be incited to practise a specific cognitive strategy (mental exercise such as "think to a music you like") and resting state measurements.
Each patient who has been recruited to fit our inclusion and non-inclusion criteria will first go through a clinical assessment of his initial judgment criteria metrics. Then subjects will go through the 5-week training and then will be evaluated on the same criteria just after the end of the therapy and at 3 months after the end of it.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||An efficiency multicentric pilot study on a targeted population for development and use of Neuro-feedback therapy for treating tinnitus.|
|Masking:||None (Open Label)|
|Official Title:||Neuro-feedback Therapy for Treating Tinnitus : Efficacy Pilot Study on a Targeted Population|
|Actual Study Start Date :||May 28, 2018|
|Estimated Primary Completion Date :||January 15, 2019|
|Estimated Study Completion Date :||January 15, 2019|
Experimental: Neuro-feedback therapy
EEG headset is placed on the patients head and the electrodes record the brain activity from F3, F4, FC1 and FC2 (on the 10-10 international localization system of EEG electrodes) and generate feedback.
Each session is composed of 6 blocks of 3 minutes in which the patient is incited to practice a specific cognitive strategy. During the 4 first session, 8 strategies are explored. Then through the therapy, the best cognitive strategies are gradually selected through an automatized process taking in account objective performances and subjective feedback.
Device: Neuro-feedback therapy
The therapy consists of 10 Neuro-feedback training sessions, 2 times per week over 5 weeks.
- Comparison of initial and final Tinnitus Handicap Inventory (THI) distributions [ Time Frame: Comparison of initial and final THI before and after treatment for a Time frame of 5 weeks. ]This primary outcome measure denotes the evolution of the deterioration of the quality of life of patients due to tinnitus. THI is a questionnaire composed of 25 questions each with 3 response options converting in 0, 2, and 4 points scoring, making it a scale from 0 to 100 points.
- Comparison of initial and final Visual Analog Scale (VAS) distributions [ Time Frame: Comparison of initial and final VAS before and after treatment for a Time frame of 5 weeks. ]The secondary outcome measure denotes the evolution of the intensity of tinnitus and the disturbance associated measured by two scales. First the Visual Analog Scale (VAS) for intensity of Tinnitus enables the patient to rate his tinnitus intensity with integers values between 1 to 10 (included). Second, the Visual Analog Scale (VAS) for Tinnitus associated disturbance enables the patient to rate his tinnitus associated diturbance with integers values between 1 to 10 (included). For both scales, a high value (near 10) indicates a high gravity of the symptom, regarding either its intensity or its associated disturbance, while low values (near 1), indicate lighter impact of the symptom regarding its intensity or its associated disturbance. The scores are assessed subjectively by the patient when asked.
- Evolution of Tinnitus Handicap Inventory (THI) and Visual Analog Scales (VAS) on tinnitus intensity and associated disturbance 3 month after the treatment [ Time Frame: 3 months after the end of the 5 week treatment ]Evaluation of maintenance of effects perceived 3 months after the treatment. The THI and the VAS scales are used similarly to the precedent outcome measures. THI is a questionnaire composed of 25 questions each with 3 response options converting in 0, 2, and 4 points scoring, making it a scale from 0 to 100 points. the Visual Analog Scale (VAS) for intensity of Tinnitus enables the patient to rate his tinnitus intensity with integers values between 1 to 10 (included). The Visual Analog Scale (VAS) for Tinnitus associated disturbance enables the patient to rate his tinnitus associated diturbance with integers values between 1 to 10 (included). For both visual analog scales, a high value (near 10) indicates a high gravity of the symptom, regarding either its intensity or its associated disturbance, while low values (near 1), indicate lighter impact of the symptom regarding its intensity or its associated disturbance.
- Side effects [ Time Frame: The total duration of the study ]Evaluation of potential side effects during the study. At each session patients will be asked if they want to declare any side effects they believe to be related to the treatment.
- Evolution of pathological attention level (BAHIA) standing for (in french) Biphasique, Acouphène, Hyperacousie, Insensibilité de la face et Autres sensations. [ Time Frame: Comparison of initial and final BAHIA before and after treatment for a Time frame of 5 weeks. ]Evaluation of the proportion of daily time that the patient reports experiencing and being disturbed by his tinnitus through 4 questions.
- Correlation of the electrophysiological measurements and the THI/VAS measurements [ Time Frame: Over the 5 weeks of treatment ]Correlation between the plastic effects induced by therapy on electrophysiological measurements and the assessment of the severity of tinnitus through the THI/VAS.
- Evolution of the THI, BAHIA, and VAS scores, expressed as a percentage of the initial value [ Time Frame: Comparison of initial and final measurements before and after treatment for a Time frame of 5 weeks. ]Evolution of the precedent quoted measures before and after treatment measured as percentages of the initial value (proportion of evolution of the THI, VAS and BAHIA measurements).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03773926
|Contact: Alain LONDERO||05 61 77 21 19||Alain.email@example.com|
|Contact: Renaud SIMEON||01 40 19 36 firstname.lastname@example.org|
|Audika Research Center||Recruiting|
|Paris, Ile De France, France, 75005|
|Contact: ROBIN GUILLARD 0033642480836 email@example.com|
|Contact: THOMAS CERVONI 0033638895203 firstname.lastname@example.org|
|Principal Investigator: ALAIN LONDERO|
|Sub-Investigator: RENAUD SIMEON|
|Purpan University hospital||Recruiting|
|Toulouse, Languedoc-Roussillon-Midi-Pyrénées, France, 31300|
|Contact: Jonathan SCHMUTZ 0033634390378 email@example.com|
|Contact: Agnès AGASSE 00335 61 77 77 70|
|Principal Investigator: Marie-Josée FRAYSSE|
|Principal Investigator:||Marie-Josée FRAYSSE||University Hospital, Toulouse|